Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis

Wei Li Zhao, Lan Wang, Yuan Hua Liu, Jin Song Yan, Christophe Leboeuf, Yan Yan Liu, Wei Li Wu, Anne Janin, Zhu Chen, Sai Juan Chen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The anti-CD20 monoclonal antibody rituximab has shown promising results in the clinical treatment of patients with B-cell non-Hodgkin's lymphoma (B-NHL). However, its therapeutic effect could still be improved. Methods: This study examined the anti-tumor activity of rituximab combined with histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in CD20-positive B-NHL cell lines, as well as in primary B-NHL cells and a murine B-NHL model. Results: The combination treatment sensitized B-NHL cells to apoptosis in a synergistic manner, concomitant with mitochondrial instability and Bcl-2/Bcl-XL downregulation. Particularly in Daudi cells relatively resistant to rituximab, these events were associated with nuclear factor-κB (NF-κB) inactivation and c-Myc degradation. SAHA presented functional complementation with rituximab, through decreasing IKKα/β and IκBα phosphorylation, thus preventing NF-κB nuclear translocation. In addition, SAHA induced IκBα cleavage to a stable inhibitory form and caused NF-κB degradation in response to caspase-3 activation. More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells. Conclusion: These findings emphasized the value of targeting apoptosis signaling pathway in lymphoma therapy. Rituximab in conjunction with histone deacetylase inhibitor may represent a novel strategy in treating patients with B-NHL.

Original languageEnglish (US)
Pages (from-to)1801-1811
Number of pages11
JournalExperimental Hematology
Volume35
Issue number12
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Apoptosis
Lymphoma
SCID Mice
Therapeutic Uses
Rituximab
Intravenous Injections
Caspase 3
Therapeutics
Down-Regulation
Monoclonal Antibodies
Phosphorylation
Cell Line
Survival
vorinostat

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Zhao, W. L., Wang, L., Liu, Y. H., Yan, J. S., Leboeuf, C., Liu, Y. Y., ... Chen, S. J. (2007). Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Experimental Hematology, 35(12), 1801-1811. https://doi.org/10.1016/j.exphem.2007.06.009

Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. / Zhao, Wei Li; Wang, Lan; Liu, Yuan Hua; Yan, Jin Song; Leboeuf, Christophe; Liu, Yan Yan; Wu, Wei Li; Janin, Anne; Chen, Zhu; Chen, Sai Juan.

In: Experimental Hematology, Vol. 35, No. 12, 12.2007, p. 1801-1811.

Research output: Contribution to journalArticle

Zhao, WL, Wang, L, Liu, YH, Yan, JS, Leboeuf, C, Liu, YY, Wu, WL, Janin, A, Chen, Z & Chen, SJ 2007, 'Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis', Experimental Hematology, vol. 35, no. 12, pp. 1801-1811. https://doi.org/10.1016/j.exphem.2007.06.009
Zhao, Wei Li ; Wang, Lan ; Liu, Yuan Hua ; Yan, Jin Song ; Leboeuf, Christophe ; Liu, Yan Yan ; Wu, Wei Li ; Janin, Anne ; Chen, Zhu ; Chen, Sai Juan. / Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. In: Experimental Hematology. 2007 ; Vol. 35, No. 12. pp. 1801-1811.
@article{4cfe4edfa15d427584b1b3ace37a803d,
title = "Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis",
abstract = "Objective: The anti-CD20 monoclonal antibody rituximab has shown promising results in the clinical treatment of patients with B-cell non-Hodgkin's lymphoma (B-NHL). However, its therapeutic effect could still be improved. Methods: This study examined the anti-tumor activity of rituximab combined with histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in CD20-positive B-NHL cell lines, as well as in primary B-NHL cells and a murine B-NHL model. Results: The combination treatment sensitized B-NHL cells to apoptosis in a synergistic manner, concomitant with mitochondrial instability and Bcl-2/Bcl-XL downregulation. Particularly in Daudi cells relatively resistant to rituximab, these events were associated with nuclear factor-κB (NF-κB) inactivation and c-Myc degradation. SAHA presented functional complementation with rituximab, through decreasing IKKα/β and IκBα phosphorylation, thus preventing NF-κB nuclear translocation. In addition, SAHA induced IκBα cleavage to a stable inhibitory form and caused NF-κB degradation in response to caspase-3 activation. More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells. Conclusion: These findings emphasized the value of targeting apoptosis signaling pathway in lymphoma therapy. Rituximab in conjunction with histone deacetylase inhibitor may represent a novel strategy in treating patients with B-NHL.",
author = "Zhao, {Wei Li} and Lan Wang and Liu, {Yuan Hua} and Yan, {Jin Song} and Christophe Leboeuf and Liu, {Yan Yan} and Wu, {Wei Li} and Anne Janin and Zhu Chen and Chen, {Sai Juan}",
year = "2007",
month = "12",
doi = "10.1016/j.exphem.2007.06.009",
language = "English (US)",
volume = "35",
pages = "1801--1811",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis

AU - Zhao, Wei Li

AU - Wang, Lan

AU - Liu, Yuan Hua

AU - Yan, Jin Song

AU - Leboeuf, Christophe

AU - Liu, Yan Yan

AU - Wu, Wei Li

AU - Janin, Anne

AU - Chen, Zhu

AU - Chen, Sai Juan

PY - 2007/12

Y1 - 2007/12

N2 - Objective: The anti-CD20 monoclonal antibody rituximab has shown promising results in the clinical treatment of patients with B-cell non-Hodgkin's lymphoma (B-NHL). However, its therapeutic effect could still be improved. Methods: This study examined the anti-tumor activity of rituximab combined with histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in CD20-positive B-NHL cell lines, as well as in primary B-NHL cells and a murine B-NHL model. Results: The combination treatment sensitized B-NHL cells to apoptosis in a synergistic manner, concomitant with mitochondrial instability and Bcl-2/Bcl-XL downregulation. Particularly in Daudi cells relatively resistant to rituximab, these events were associated with nuclear factor-κB (NF-κB) inactivation and c-Myc degradation. SAHA presented functional complementation with rituximab, through decreasing IKKα/β and IκBα phosphorylation, thus preventing NF-κB nuclear translocation. In addition, SAHA induced IκBα cleavage to a stable inhibitory form and caused NF-κB degradation in response to caspase-3 activation. More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells. Conclusion: These findings emphasized the value of targeting apoptosis signaling pathway in lymphoma therapy. Rituximab in conjunction with histone deacetylase inhibitor may represent a novel strategy in treating patients with B-NHL.

AB - Objective: The anti-CD20 monoclonal antibody rituximab has shown promising results in the clinical treatment of patients with B-cell non-Hodgkin's lymphoma (B-NHL). However, its therapeutic effect could still be improved. Methods: This study examined the anti-tumor activity of rituximab combined with histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in CD20-positive B-NHL cell lines, as well as in primary B-NHL cells and a murine B-NHL model. Results: The combination treatment sensitized B-NHL cells to apoptosis in a synergistic manner, concomitant with mitochondrial instability and Bcl-2/Bcl-XL downregulation. Particularly in Daudi cells relatively resistant to rituximab, these events were associated with nuclear factor-κB (NF-κB) inactivation and c-Myc degradation. SAHA presented functional complementation with rituximab, through decreasing IKKα/β and IκBα phosphorylation, thus preventing NF-κB nuclear translocation. In addition, SAHA induced IκBα cleavage to a stable inhibitory form and caused NF-κB degradation in response to caspase-3 activation. More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells. Conclusion: These findings emphasized the value of targeting apoptosis signaling pathway in lymphoma therapy. Rituximab in conjunction with histone deacetylase inhibitor may represent a novel strategy in treating patients with B-NHL.

UR - http://www.scopus.com/inward/record.url?scp=36248959806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248959806&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2007.06.009

DO - 10.1016/j.exphem.2007.06.009

M3 - Article

VL - 35

SP - 1801

EP - 1811

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 12

ER -